Manufacturers Trader Service OEM

Shanghai Fosun Med-Tech Development Co., Ltd.

No. 830 Chengyin Road , 200444 Shanghai
China, People's Republic of

Telephone +86 21 60765718
Fax +86 21 60765999
shengli@fosunpharma.com

Trade fair hall

  • Hall 3 / J26
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 3): stand J26

Fairground map

MEDICA 2016 fairground map: Hall 3

Contact

Shirly Sheng

Phone
862160765718

Email
shengli@fosunpharma.com

Visit us

Hall 3 / J26

14.11.2016

Topic

Download

all-day

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf.

Shanghai, China and Oxford, England – Fosun Diagnostics and GeneFirst Ltd announced that the companies will be attending Medica 2016, in Dusseldorf . The two companies have been collaborating since 2014, enabling Fosun Diagnostics to access GeneFirst’s broad technology portfolio, including the MMD-PCR (Multiple Mutation Detection Polymerase Chain Reaction) and MPA (Multiplex Probe Amplification) platforms.   

GeneFirst’ proprietary MMD-PCR technology is a real-time PCR-based diagnostic technology intended for detection of cancer-associated mutations in DNA extracted from either blood or formalin-fixed, paraffin-embedded (FFPE) tissue material. These robust diagnostic assays can even detect low number of mutated DNA in a high background of normal genetic material. In 2015 Fosun commercialised the first of these kits (Kras, BRAF and EGFR) and obtained CE Marking for distribution across Europe. Genefirst offers Oncoplex - an extended line of cancer gene testing assays detecting expanded mutations, these genes include Kras, BRAF, EGFR, Jak2, PIK3CA, Nras and ABL. The products feature: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.

‘We are extremely excited to be collaborating with Fosun Diagnostics’, stated Guoliang Fu, CEO of GeneFirst. ‘Our MMD technology enables increased sensitivity of mutant alleles constituting as little as 0.1% to 1% and higher throughput due to its ability to detect several different mutations in a single closed-tube reaction’.

Based on Genefirst’s MPA technology, Genefirst and Fosun have recently launched Papilloplex HR HPV test as CE IVD. MPA is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capability. Papilloplex HR-HPV Genotyping Assay is a product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

The two companies will continue to collaborate building on the first generation of products by expanding the number of mutations for each kit and extending the existing range by introducing new products.

About GeneFirst

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine.

GeneFirst offers simple, affordable and reliable molecular diagnostics technologies and products to researchers, clinicians and drug companies, to enable accurate diagnosis and the delivery of safe and effective medicines.

GeneFirst offers two product lines:

Papilloplex® HR HPV, a molecular diagnostic kit for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

Oncoplex, a range of cancer mutation detection kits, based on the Multiple Mutation Detection Polymerase Chain Reaction (MMD-PCR) technology.

For more information, visit www.genefirst.com or contact info@genefirst.com

About Fosun Diagnostics

Fosun Diagnostics is one of the largest IVD manufacturers and distributors in China with products covering the four segments of In-Vitro Diagnostics: Biochemistry, Molecular Diagnostics, Microbiology and Immunology. With 28 local sales offices around China and more than 150 sales engineers, Fosun Diagnostics has successfully expanded its business nationwide with a high profile presence in the domestic market.

For more information please visit www.fosun_diagnostics.com, or contact diagnostics@fosunphar.com.

More Less

15.11.2016

Topic

Download

all-day

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf.

Shanghai, China and Oxford, England – Fosun Diagnostics and GeneFirst Ltd announced that the companies will be attending Medica 2016, in Dusseldorf . The two companies have been collaborating since 2014, enabling Fosun Diagnostics to access GeneFirst’s broad technology portfolio, including the MMD-PCR (Multiple Mutation Detection Polymerase Chain Reaction) and MPA (Multiplex Probe Amplification) platforms.   

GeneFirst’ proprietary MMD-PCR technology is a real-time PCR-based diagnostic technology intended for detection of cancer-associated mutations in DNA extracted from either blood or formalin-fixed, paraffin-embedded (FFPE) tissue material. These robust diagnostic assays can even detect low number of mutated DNA in a high background of normal genetic material. In 2015 Fosun commercialised the first of these kits (Kras, BRAF and EGFR) and obtained CE Marking for distribution across Europe. Genefirst offers Oncoplex - an extended line of cancer gene testing assays detecting expanded mutations, these genes include Kras, BRAF, EGFR, Jak2, PIK3CA, Nras and ABL. The products feature: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.

‘We are extremely excited to be collaborating with Fosun Diagnostics’, stated Guoliang Fu, CEO of GeneFirst. ‘Our MMD technology enables increased sensitivity of mutant alleles constituting as little as 0.1% to 1% and higher throughput due to its ability to detect several different mutations in a single closed-tube reaction’.

Based on Genefirst’s MPA technology, Genefirst and Fosun have recently launched Papilloplex HR HPV test as CE IVD. MPA is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capability. Papilloplex HR-HPV Genotyping Assay is a product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

The two companies will continue to collaborate building on the first generation of products by expanding the number of mutations for each kit and extending the existing range by introducing new products.

About GeneFirst

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine.

GeneFirst offers simple, affordable and reliable molecular diagnostics technologies and products to researchers, clinicians and drug companies, to enable accurate diagnosis and the delivery of safe and effective medicines.

GeneFirst offers two product lines:

Papilloplex® HR HPV, a molecular diagnostic kit for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

Oncoplex, a range of cancer mutation detection kits, based on the Multiple Mutation Detection Polymerase Chain Reaction (MMD-PCR) technology.

For more information, visit www.genefirst.com or contact info@genefirst.com

About Fosun Diagnostics

Fosun Diagnostics is one of the largest IVD manufacturers and distributors in China with products covering the four segments of In-Vitro Diagnostics: Biochemistry, Molecular Diagnostics, Microbiology and Immunology. With 28 local sales offices around China and more than 150 sales engineers, Fosun Diagnostics has successfully expanded its business nationwide with a high profile presence in the domestic market.

For more information please visit www.fosun_diagnostics.com, or contact diagnostics@fosunphar.com.

More Less

16.11.2016

Topic

Download

all-day

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf.

Shanghai, China and Oxford, England – Fosun Diagnostics and GeneFirst Ltd announced that the companies will be attending Medica 2016, in Dusseldorf . The two companies have been collaborating since 2014, enabling Fosun Diagnostics to access GeneFirst’s broad technology portfolio, including the MMD-PCR (Multiple Mutation Detection Polymerase Chain Reaction) and MPA (Multiplex Probe Amplification) platforms.   

GeneFirst’ proprietary MMD-PCR technology is a real-time PCR-based diagnostic technology intended for detection of cancer-associated mutations in DNA extracted from either blood or formalin-fixed, paraffin-embedded (FFPE) tissue material. These robust diagnostic assays can even detect low number of mutated DNA in a high background of normal genetic material. In 2015 Fosun commercialised the first of these kits (Kras, BRAF and EGFR) and obtained CE Marking for distribution across Europe. Genefirst offers Oncoplex - an extended line of cancer gene testing assays detecting expanded mutations, these genes include Kras, BRAF, EGFR, Jak2, PIK3CA, Nras and ABL. The products feature: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.

‘We are extremely excited to be collaborating with Fosun Diagnostics’, stated Guoliang Fu, CEO of GeneFirst. ‘Our MMD technology enables increased sensitivity of mutant alleles constituting as little as 0.1% to 1% and higher throughput due to its ability to detect several different mutations in a single closed-tube reaction’.

Based on Genefirst’s MPA technology, Genefirst and Fosun have recently launched Papilloplex HR HPV test as CE IVD. MPA is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capability. Papilloplex HR-HPV Genotyping Assay is a product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

The two companies will continue to collaborate building on the first generation of products by expanding the number of mutations for each kit and extending the existing range by introducing new products.

About GeneFirst

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine.

GeneFirst offers simple, affordable and reliable molecular diagnostics technologies and products to researchers, clinicians and drug companies, to enable accurate diagnosis and the delivery of safe and effective medicines.

GeneFirst offers two product lines:

Papilloplex® HR HPV, a molecular diagnostic kit for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

Oncoplex, a range of cancer mutation detection kits, based on the Multiple Mutation Detection Polymerase Chain Reaction (MMD-PCR) technology.

For more information, visit www.genefirst.com or contact info@genefirst.com

About Fosun Diagnostics

Fosun Diagnostics is one of the largest IVD manufacturers and distributors in China with products covering the four segments of In-Vitro Diagnostics: Biochemistry, Molecular Diagnostics, Microbiology and Immunology. With 28 local sales offices around China and more than 150 sales engineers, Fosun Diagnostics has successfully expanded its business nationwide with a high profile presence in the domestic market.

For more information please visit www.fosun_diagnostics.com, or contact diagnostics@fosunphar.com.

More Less

17.11.2016

Topic

Download

all-day

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf

Fosun Diagnostics and GeneFirst to exhibit at Medica 2016 in Dusseldorf.

Shanghai, China and Oxford, England – Fosun Diagnostics and GeneFirst Ltd announced that the companies will be attending Medica 2016, in Dusseldorf . The two companies have been collaborating since 2014, enabling Fosun Diagnostics to access GeneFirst’s broad technology portfolio, including the MMD-PCR (Multiple Mutation Detection Polymerase Chain Reaction) and MPA (Multiplex Probe Amplification) platforms.   

GeneFirst’ proprietary MMD-PCR technology is a real-time PCR-based diagnostic technology intended for detection of cancer-associated mutations in DNA extracted from either blood or formalin-fixed, paraffin-embedded (FFPE) tissue material. These robust diagnostic assays can even detect low number of mutated DNA in a high background of normal genetic material. In 2015 Fosun commercialised the first of these kits (Kras, BRAF and EGFR) and obtained CE Marking for distribution across Europe. Genefirst offers Oncoplex - an extended line of cancer gene testing assays detecting expanded mutations, these genes include Kras, BRAF, EGFR, Jak2, PIK3CA, Nras and ABL. The products feature: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.

‘We are extremely excited to be collaborating with Fosun Diagnostics’, stated Guoliang Fu, CEO of GeneFirst. ‘Our MMD technology enables increased sensitivity of mutant alleles constituting as little as 0.1% to 1% and higher throughput due to its ability to detect several different mutations in a single closed-tube reaction’.

Based on Genefirst’s MPA technology, Genefirst and Fosun have recently launched Papilloplex HR HPV test as CE IVD. MPA is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capability. Papilloplex HR-HPV Genotyping Assay is a product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

The two companies will continue to collaborate building on the first generation of products by expanding the number of mutations for each kit and extending the existing range by introducing new products.

About GeneFirst

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine.

GeneFirst offers simple, affordable and reliable molecular diagnostics technologies and products to researchers, clinicians and drug companies, to enable accurate diagnosis and the delivery of safe and effective medicines.

GeneFirst offers two product lines:

Papilloplex® HR HPV, a molecular diagnostic kit for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

Oncoplex, a range of cancer mutation detection kits, based on the Multiple Mutation Detection Polymerase Chain Reaction (MMD-PCR) technology.

For more information, visit www.genefirst.com or contact info@genefirst.com

About Fosun Diagnostics

Fosun Diagnostics is one of the largest IVD manufacturers and distributors in China with products covering the four segments of In-Vitro Diagnostics: Biochemistry, Molecular Diagnostics, Microbiology and Immunology. With 28 local sales offices around China and more than 150 sales engineers, Fosun Diagnostics has successfully expanded its business nationwide with a high profile presence in the domestic market.

For more information please visit www.fosun_diagnostics.com, or contact diagnostics@fosunphar.com.

More Less

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.02  DNA diagnosis kits

DNA diagnosis kits

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Gene tests / molecular biological diagnostic

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.08  Devices and systems for glucose determination units

Devices and systems for glucose determination units

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology

Bacteriology

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.02  Bacteriology - Identification and susceptibility testing

Bacteriology - Identification and susceptibility testing

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.05  Equipment and systems for microbiological diagnosis/virology

Equipment and systems for microbiological diagnosis/virology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.05  Equipment and systems for microbiological diagnosis/virology
  • 03.05.05.02  Equipment for microbiological diagnosis

Equipment for microbiological diagnosis

Our products

Product category: Gene tests / molecular biological diagnostic

Microbial Identification System& Antimicrobial Susceptibility System

Identification System  (ID System)

Antimicrobial Susceptibility System (AST System)

---Refer to the Most Recent CLSI M100 and FDA Performance Standard on MIC Tests
---Most Regular Antimicrobial Agents with Predefined Gradient Concentrations
---Various Designs with corresponding interpretive standards for different genus in Non-Lactose-Fermenting Bacteria
---Professional Prompt on Mechanisms of  ESBLs、MRSA、VRE Resistance mechanisms
---Integrated AST MicroPlate with Selected Strips Offers Flexibility in Testing New Antimicrobials

ONE BASIC TESTING PROTOCOL

---The same protocol is used for all identification and MIC tests, consisting of following steps

More Less

Company news

Date

Topic

Download

Nov 13, 2016

Fosun Diagnostics present new product line in MEDICA 2016

Fosunpharma Diagnostics will be attending MEDICA in Dusseldorf, Germany during 14th Nov-17th Nov. Our booth number is 3J26. We would like to see you at our booth!

This year we will present our new product line --- POCT for Clinical Chemsitry. Based on two different methods, photochemistry and electrochemistry, our POCT analyzers provide 8 tests including Uric Acid(UA), Urea Nitrogen(UN), Creatinine, Blood Ketone, Cholesterol, Triglycerides, Hemoglobin,Blood Glucose. In addition, we have two POCT analyzers for Renal Function 3 in 1 and Lipid Test 3 in 1. The results could be read within several seconds. Please contact us for more information.

Also, we will be presenting CE approved Automated Blood Culture System-- Pioneer! We are looking for distributors all over the world, please let us know if you are interested. 

Last but not least, in the section of Molecular Diagnostics, we will present LM2012, Six Channel Real Time PCR Analyzer and FD-SLA-32, Nucleic Acid Extractor will be presented as well as Real Time PCR Kits including HPV, HBV, HCV, STD, Cancer Gene Mutation,etc. Our genotyping kits are HPV 23, Thalassemia, Y Chromosome Microdeletions, HBV, MTB, Mytobacerium Species Identification,ect will also been shown during MEDICA.

For more information and demonstration,  you are more than welcome to visit our booth in Hall 3, stand J26.  We look forward to seeing you soon in MEDICA.

More Less

About us

Company details

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is founded in 1994, and in Jul 1998 it successfully got listed in Shanghai Stock Exchange (Stock NO. 600196).

Focused on modern bio-medicine & health-care industry, Fosun Pharma has formed its core competences in R&D, marketing, M&A, and HR management after years of development, and now it is a large professional pharmaceutical group, mainly in medicine research and manufacturing, with leading market share in medicine distribution, diagnostic products and medical equipments.

In China, Fosun Pharma has obtained a leading position in segment markets, ie, hepatic medicines, gynecological medicines, diabetes medicines, clinical diagnostical products, and stomatological therapeutic equipment, etc. In the global market, Fosun Pharma is well known for its anti-malaria medicine and various active pharmaceutical ingredients.

At present, taking the advantage of the rapid growth of Chinese medicine industry and generic drug in the European and American mainstream markets, Fosun Pharma pushes forward its innovation, brand, cost and internationalization strategies to realize its robust management and fast development.

Looking forward to the future, Fosun Pharma will continue shouldering its social responsibilities, pay attention to the construction of personnel and working team, integrate medicine industry resources, and finally improve its core competence and realize its strategic target of being a first-class enterprise in the global mainstream markets.

More Less

Company data

Sales volume

10-49 Mio US $

Export content

max. 10%

Number of employees

100-499

Foundation

1989

Area of business

Diagnostics

Company information as a PDF file